Biology before Anatomy in Early Breast Cancer--Precisely the Point.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review.Breast cancer research : BCR · 2020
   Pooled it
2. Screening for reducing morbidity and mortality in malignant melanoma.The Cochrane database of systematic reviews · 2019
   Pooled it
3. Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancer.NPJ breast cancer · 2025
   Review
4. Comparison of Recurrence Risk Prediction by the CanAssist Breast Test and the PREDICT Online Tool in Early Breast Cancer Patients.Cureus · 2025
   Article
5. Differences in clinicopathologic features and subtype distribution of invasive breast cancer between elderly and non-elderly women.Fujita medical journal · 2021
   Article
6. Omics Integration Analyses Reveal the Early Evolution of Malignancy in Breast Cancer.Cancers · 2020
   Article
7. Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential.Histopathology · 2019
   Article
8. Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.Cancer medicine · 2019
   Article
9. Inverse correlation between Ki67 expression as a continuous variable and outcomes in luminal HER2-negative breast cancer.Fujita medical journal · 2019
   Article
10. Differences in clinicopathologic features and subtype distribution of invasive breast cancer between women older and younger than 40 years.Fujita medical journal · 2019
    Article
11. The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study.Diagnostic and prognostic research · 2019
    Article
12. Clinical implication of subcategorizing T2 category into T2a and T2b in TNM staging of breast cancer.Cancer medicine · 2018
    Article
13. Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer.Oncology letters · 2018
    Article
14. Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer.Biomarker insights · 2018
    Article
15. 21-gene recurrence assay in patients receiving intraoperative radiotherapy: are "favorable" characteristics a surrogate for low recurrence?Gland surgery · 2017
    Article
16. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017
    Article
17. The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.Breast cancer research and treatment · 2017
    Article
18. The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients.Breast cancer research and treatment · 2017
    Article
19. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.Cancer · 2017
    Article
20. Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer.Cancer · 2017
    Article

Corrections and comments

• Comment on
  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.2015

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as